ArticlePloS one2025
Prevalence of double heterozygotes of HbE and α-thal 1 (SEA) type in pregnancies and their partners that received antenatal care at Chiangrai Prachanukroh Hospital and reevaluated the cut-offs for differentiation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoplate Digital PCR for Identification of αInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Thailand, double heterozygotes of HbE and α-thal 1 (SEA) type is common. If pregnant women carrying this genotype conceive with partners who also carry the same genotype or who are carriers of α-thalassemia 1 (SEA) type, there is 25% chance of a fetus having Hb Bart's hydrops fetalis. This research aims to determine the prevalence of double SEA/E, compare the hematological parameters and HbE levels between pure HbE heterozygote and double SEA/E and reevaluate the cut-offs used to screen individuals with these genotypes.
methodsIn a retrospective study, 397 samples from individuals (partners who visited the Antenatal Care Clinic, Chiangrai Prachanukroh Hospital, Chiangrai Province, from 2017-2021) with HbE (hemoglobin typing EA) were collected. The samples were then classified as HbE with or without α-thalassemia 1 (SEA) type and RBC, Hb, Hct, MCV, MCH, MCHC, RDW and HbE level were compared between pure HbE heterozygote and double SEA/E via Student's t-test, with a p-value of 0.05. Cut-offs were reevaluated in samples that avoided interfering with iron-deficiency anemia via the parameters of sensitivity, specificity, PPV, NPV and accuracy.
resultsThe study revealed that the prevalence of double heterozygotes of HbE and α-thal 1 (SEA) type was 12.6%. HbE level, MCV, MCH and MCHC in double heterozygotes of HbE and α-thal 1 (SEA) type were significantly lower, whereas RBC and RDW were greater (p < 0.001). Reevaluation for cut-offs revealed that, in the group with Hb < 10.0 g/dL, combined cut-offs (MCH + HbE level) and (MCV + MCH + HbE level) for the group with Hb = 10.0-11.9 g/dL were most effective, while a single cut-off (HbE level) was most effective for the group with Hb ≥ 12.0 g/dL.
conclusionsDouble SEA/E were also common among pregnant women and their partners who visited Chiangrai Prachanukroh Hospital, Chiangrai, Thailand. Using appropriate cut-offs for hematological parameters and HbE levels allows pure HbE heterozygote to be distinguished from double SEA/E.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.